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To evaluate, according to the histologic type and initial stage, the mean cost (MC) of managing patients with lung cancer and the costs
of the different management phases. A Markov approach was used to model these costs, based on the management of a
representative nation-wide sample of 428 patients with newly diagnosed lung cancer. The 18-month MC ranged from US$ 20691
(95% CI: 5777–50380 for diffuse non-small-cell lung cancer (NSCLC) to US$ 31833 (95% CI: 15866–64455) for localised small-
cell lung cancer (SCLC); first-line treatment costs ranged from 33.8% of MC for medically inoperable localised NSCLC to 74.6% for
diffuse SCLC; second- or third-line treatment costs ranged from 7.8% of MC for surgically treated localised NSCLC to 32% for locally
advanced NSCLC; and the cost of palliative care ranged from 9.1% of MC for locally advanced NSCLC to 39.9% for medically
inoperable localised NSCLC. The cost of first-line chemotherapy and the percentage of actively treated patients impacted more on
MC than did the cost of second- or third-line chemotherapy regimens or the cost of palliative care. In conclusion, this model provides
a robust economic analysis of the cost of lung cancer management, and will be useful for assessing the economic consequences of
future changes in patient management.
British Journal of Cancer (2004) 90, 397–402. doi:10.1038/sj.bjc.6601547 www.bjcancer.com
& 2004 Cancer Research UK
Keywords: Markov model; management; lung cancer; economic analysis
                                              
Lung cancer is one of the most serious public health problems in
industrialised countries. Several studies have shown the high cost
of this malignancy for health-care systems (Goodwin and
Shepherd, 1998), leading to profound reflections in an era of
health cost rationalisation (Berthelot et al, 2000; Bahl and Falk,
2001). Indeed, the incidence of lung cancer is increasing rapidly,
and new costly antimitotic agents are yielding a moderate but
significant survival increment. Previously, economic studies in this
area are based on data extracted from randomised clinical trials
and expert reports (Evans et al, 1995, 1997; Evans, 1997; Earle and
Evans, 1999) or are purely descriptive (Hillner et al, 1998;
Wolstenholme and Whynes, 1999). Costly drugs used for the
active treatment of lung cancer have also been the subject of cost-
efficacy studies, generally comparing two alternative therapies and
being limited to the initial treatment phase (Jaakkimainen et al,
1990; Goodwin et al, 1988).
These previous studies have several limitations. First, they were
rarely based on routine management of a representative patient
sample. Second, the models were based on expert opinion, which
can differ somewhat from real practices. Third, data taken from
clinical trials are unrepresentative, in terms of the patient
population and management practices (Cottin et al, 1999). Finally,
the management of lung cancer is becoming more complex, and
the emergence of new antimitotic drugs calls for individual
analysis of the respective costs of the different phases of patient
management, especially those linked to first-line treatments, active
second- or third-line treatments, and palliative care; costs must
also be analysed according to the stage at diagnosis, which
determines the chosen treatment strategy.
The aim of this study, based on the records of a sample of
patients drawn from a French nationwide survey, was to assess the
mean cost (MC) of the clinical management of lung cancer and the
costs of the different management phases. We modelled these costs
in order to assess the economic impact of the percentage of
actively treated patients and the types of chemotherapy used.
METHODS
Based on a sample of patients with lung cancer who were
representative of the French national population of such patients,
we examined management practices and their costs. A Markov
model was used to calculate the MC of patient management
according to the histologic type and extension stage at initial
diagnosis, and the respective costs of the different treatment
phases.
The Markov model (Sonnenberg and Beck, 1993; Chouaid et al,
1998) is a multistate transitory model in which patients make
transitions among various health states, at different rates, over
extended periods. All clinically important events are modelled as
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ltransitions from one state to another. The passage of time is
divided into intervals called cycles, which are chosen to represent a
clinically meaningful time interval. During each cycle, each
member of the cohort may remain in the same state of health or
move to another state, except when the state is ‘absorbing’. In this
way, lung cancer management can be modelled as follows: at
diagnosis, the initial assessment (histologic type, stage, patient’s
age and general status) orients the management decision towards
active treatment combining radiotherapy, chemotherapy and/or
surgery, depending on the case (state L1: first-line treatment), or
palliative care (state PC: no active treatment). When active
treatment is undertaken, regular clinical assessment of efficacy
and tolerability determines subsequent management, that is,
pursuit of the same treatment (state L1); a second- or third-line
treatment (state L2); simple monitoring for patients in partial or
complete remission (state R); or palliative care for patients with
disease progression (state PC). In other words, between each
clinical assessment, each patient (Figure 1) is in one of the
following five health states: L1, L2, R, PC or death. These health
states are mutually exclusive and collectively exhaustive.
Primary data sources and identification of baseline and
transition probabilities
Baseline probabilities and probabilities of transition from one state
of health to another over time were established by analysing the
management modalities of all consecutive new cases of lung cancer
diagnosed between 1 July 1998 and 30 June 1999 in a representative
French national sample of health-care centres managing lung
cancer. In order to avoid including too many centres treating very
few patients with potentially unrepresentative management
approaches, only centres treating more than 50 cases of lung
cancer annually were selected. One in 10 centres meeting this
criterion were randomly selected after stratification, according to
the type of establishment (in France, 30% of patients with lung
cancer are treated in public university hospitals, 25% in
nonuniversity public hospitals, 20% in cancer treatment centres
and 25% in private establishments). On the basis of current
international recommendations (Johnson, 1999; Hoffman et al,
2000), patients are categorised into seven homogeneous sub-
groups, two for small-cell lung cancer (SCLC) (localised and
diffuse forms) and five for non-small-cell lung cancer (NSCLC),
namely localised and initially operable, localised and medically
inoperable, locally advanced receiving neoadjuvant treatment,
inoperable locally advanced and diffuse forms. The sample size
was calculated to obtain at least 20 patients in each subgroup.
Patients managed in each institution were identified from
individual medical data management systems (diagnosis-related
groups, DRGs), by searching for all patients who consulted or were
admitted to a medical or surgical ward with a principal diagnosis
of lung cancer or suspected lung cancer, and by analysing all new
radiotherapy-based treatments started during the study period.
Patients treated for relapse and patients treated in clinical research
trials were excluded. The analysis, which spanned the 18 months
that followed diagnosis, or the period from diagnosis to death,
focused on all events related to lung cancer that entailed the
consumption of medical resources, including adverse effects of
treatment necessitating hospitalisation, and patient transportation.
Data were collected from patient charts by specially trained clinical
research technicians. The physicians in charge of each patient were
contacted to obtain data missing from the files. The exhaustive
nature of patient enrollments and data collection in each centre
were verified by two of the authors (LM and AV). We
distinguished among the different management phases, for each
patient and 3-month period, namely first-line treatments (surgery,
chemotherapy or radiotherapy), second- or third-line treatment
(all other active treatment periods), remission (periods in partial
or complete remission) and palliative care, defined as a lack of
conservative treatment (including palliative radiotherapy, anti-
infectives, corticosteroids and pain relief). The patients were
classified in each period by two of the authors (AV and CC).
During each period, we also took into account costs linked to
complications and patient transport. The clinical teams involved
were informed of the study after it had been completed, to avoid
influencing their practices.
Economic valorisation
The economic analysis (Desky and Naglie, 1990) adopted the
health-care payer’s perspective and took into account only direct
costs (i.e. consumption of health-care resources). Indirect costs
(e.g. lost income) and intangible costs (e.g. pain and suffering)
were not assessed. Direct costs of managing lung cancer included
hospitalisation, medical costs and transportation. Hospitalisation
costs (administration, security, maintenance, general equipment,
central supply, dietetics and social services) were assessed on a per
diem basis (national unit cost scale for each event) for fixed costs
and on drug purchase prices in the establishments concerned.
Depending on the reason for hospital admission and the length of
stay, the mean unit cost per hospital day ranged from 202US$
(day-care radiotherapy) to 656US$ (surgery). Medical procedures
performed outside the hospital and transport costs were assessed
using the national unit cost scale. Medical costs (nursing, care,
ward supplies, pharmacy, diagnostic tests, laboratory tests and
professional services) were determined retrospectively by chart
review. The volumes of resources used were identified in each 3-
month period by distinguishing the consumption linked to
surgery, chemotherapy, radiotherapy, treatment complications,
monitoring, palliative care and transportation. The initial diag-
nostic costs were not taken into account.
Markov model
Using Decision Analysis software from TreeAge
s Data 3.5.
(Williamstown, MA, USA), we analysed the expected monetary
cost of going through the Markov model. The simulation was run
as follows. In each subgroup, patients were distributed between the
L 1
L 2 
R
PC
Death
Figure 1 Modelling lung cancer management on the basis of five
mutually exclusive and collectively exhaustive health states: L1¼first-line
treatment, L2¼second- or third-line treatment, R¼remission, PC¼no
active treatment and death. The arrows represent the possible transitions
(arrows drawn to and from a given state denote the possibility of remaining
in that state during a cycle).
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ldifferent health states according to the initial probability (P0) of
being treated (state L1) and, therefore, the probability (1-P0) of
receiving palliative care (state PC). In the subsequent cycle (3-
month period), the cohort was partitioned among all the states
according to the transition probabilities; this resulted in a new
distribution of the cohort among the different states. The utility
accrued for the cycle is referred to as the cycle sum. In total, 95%
confidence intervals (CI) were obtained by Monte-Carlo simula-
tion. Groups were compared using Student’s t-test (Thompson and
Barber, 2000), run on Statview
s 4.02 (Abacus Concept Inc., USA).
Sensitivity analysis
Several sensitivity analyses were conducted to test the relevance of
the model, first, by varying, in the relevant subgroups (diffuse
SCLC, inoperable locally advanced and diffuse NSCLC), the
percentage of actively treated patients (initial probability of
treatment, P0) from 75 to 100%; then by studying the impact of
the costs of chemotherapy regimens used in first- and second- or
third-line treatments, by varying these costs by 730%; and finally
by taking into account new management practices in palliative care
(home-based care), by varying these costs by  30%. These three
analyses were applied to each subgroup.
RESULTS
Baseline data
The study included 428 patients (Table 1). The mean age was 6173
years and the male–female sex ratio was 4.66. All the patients had
a histologic or cytologic diagnosis, and the study population was
representative of the epidemiology of lung cancer in France, with
SCLC in 20.6% of cases (diffuse in 59%) and NSCLC in 79.4%. Two
patients with disseminated SCLC (3.8%), four patients with
disseminated NSCLC (2.9%) and one patient with locally advanced
NSCLC (1%) received palliative care from the outset. In all other
cases, management combined surgery (initially for localised forms,
n¼58, or after neoadjuvant treatment, n¼11) and/or radio-
therapy and/or chemotherapy (Table 1). With the exception of
patients operated on initially, all the patients can be classified, at a
given moment, in one of the following five health states: L1, L2, R,
PC or death. Initially operated patients were distributed among six
different health states, namely postoperative monitoring (POM),
L1, L2, R, PC and death. As management was standardised in most
cases, this classification was relatively straightforward. The MC of
each management modality per 3-month period is summarised in
Table 2. In the case of medically inoperable localised NSCLC, the
costs of periods L1, L2 and PC were equivalent. In the other cases,
period L1 always generated the highest costs. The cost of period L2
ranged from 38.7 to 65.1% of the cost of period L1, and the cost of
period PC ranged from 18.7 to 68.4% of the cost of period L1. The
cost breakdown for the periods of active treatment (L1 and L2)
varied considerably according to the subgroup: the cost of
chemotherapy predominated in SCLC and in locally advanced
and disseminated NSCLC; the cost of radiotherapy predominated
in medically inoperable localised NSCLC; and surgery was the
principal cost in operable NSCLC. Treatment complications
represented up to 26% of the costs, and transportation accounted
for 6–15.1%.
Application of the Markov model
The patient distributions, in each subgroup per 3-month period, in
the different health states determined the values of baseline and
transition probabilities and their changes with time (data not
shown). Running the Markov model for six cycles, and using
Monte-Carlo simulation, the MC at 18 months was, respectively,
US$ 20184 (95% CI: 3521–46393) and 31833 (95% CI: 15866–
64455) for diffuse and localised forms of SCLC. In NSCLC, it
ranged from US$ 20691 (95%: CI 5777–50380) for diffuse forms to
US$ 27794 (95% CI: 15918–25062) for locally advanced forms
treated with neoadjuvant therapy (Table 3). Differences between
the groups in both the mean and median costs (Table 3) were
significant (Po0.001). Regardless of the subgroup considered, the
standard deviations were very large, reflecting the dispersion of
costs (linked to early death, complications requiring lengthy
hospitalisation and lengthy management in palliative care units).
The costs of the different phases varied significantly (Po0.001)
according to the histologic type and stage at diagnosis. First-line
treatment costs ranged from 33.8% of MC for medically inoperable
localised NSCLC to 74.6% for diffuse SCLC; second- or third-line
treatment costs ranged from 7.8% of MC for surgically treated
localised NSCLC to 32% for locally advanced NSCLC treated with
neoadjuvant therapy; and the cost of palliative care ranged from
Table 1 Characteristics, initial stage and management modalities
Histology
NSCLC SCLC
Forms, number of patients Local Op, 58 Local Nop, 22 LA-Ad, 21 LA-Nad, 99 Diffuse, 140 Local, 36 Diffuse, 52
Age 70711.2 59711.4 5579.2 63711.3 5579.2 63 (10.9) 6379.5
Death 18 months 14 (24.1%) 14 (64%) 8 (38%) 69 (70%) 125 (89%) 23 (64%) 48 (92.3%)
Management
PC 0 0 0 1 (1%) 4 (2.9%) 0 2 (3.8%)
L1 58 (100%) 22 (100%) 22 (100%) 98 (99%) 136 (97.1%) 22 (100%) 50 (96.2%)
Surgery only 19 — — — — — —
Surgery plus 39 — 11 — — — —
Radiation — 12 — 10 — — —
Chemotherapy — 5 9 65 124 9 40
Radiochemotherapy — 5 1 23 12 27 10
L2 17 (29.3%) 5 (22.7%) 18 (85.7%) 61 (61.6%) 58 (41.4%) 13 (36.1%) 18 (34.6%)
Radiation — — 6 16 3 — —
Chemotherapy 15 5 4 17 50 9 13
Radiochemotherapy 2 — 6 30 5 4 5
NSCLC¼non-small-cell lung cancer; SCLC¼small-cell lung cancer; PC¼no active treatment; L1¼first-line treatment; L2¼second- or third-line treatment; Local
Op¼localised, initially operated; Local Nop¼localised, medically inoperable; LA-Ad¼locally advanced, neoadjuvant treatment; LA-Nad¼locally advanced, no surgery;
diffuse¼disseminated; surgery plus¼surgery combined with chemotherapy or radiotherapy.
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l9.1% of MC for locally advanced NSCLC to 39.9% for medically
inoperable localised NSCLC.
Sensitivity analysis
When the percentage of actively treated patients was increased
from 75 to 100%, the MC of diffuse SCLC, and of inoperable locally
advanced and diffuse NSCLC increased by 1.5, 0.8 and 0.76%,
respectively, per 1% increment in the proportion of actively treated
patients. The cost of chemotherapy used in first-line treatments
had the largest impact on MC of SCLC and nonlocalised NSCLC;
the cost of chemotherapy used in second- or third-line treatments
mainly impacted on the mean cost of locally advanced NSCLC, and
the cost of palliative care mainly impacted on the mean cost of
Table 2 Mean cost (US $) of each management modality, per 3-month period, according to the histologic type and stage
Cost
(US $)
Chemotherapy
(%)
Radiotherapy
(%)
Surgery
(%)
Complications
(%)
Monitoring
(%)
TC
(%)
Transport
(%)
Loc Op NSCLC (n¼58)
SOP 5352 0 0 93.5 0.1 4.8 0 1.6
L1 14812 22.4 19.6 44 7.5 0.5 0 6
L2 8976 33.6 23.6 17.4 13.7 0.8 0 10.9
R 542 0 0 0 0 86.9 0 13.1
PC 5801 0 0 0 0 0 88.9 11.1
Loc-Nop NSCLC (n¼22)
L1 8725 28.8 41.6 0 14.4 0.6 0 14.6
L2 6810 26.9 44 0 18.8 1 0 9.3
R 381 0 0 0 0 80.8 0 19.2
PC 8315 0 0 0 0 0 89.2 10.8
LA-Ad NSCLC (n¼21)
L1 15918 27.4 10.9 51 3.1 0.1 0 7.5
L2 6162 55.8 21.6 5.5 2.9 0.8 0 13.4
R 484 0 0 0 0 88.8 0 11.2
PC 2982 0 0 0 0 0 96.3 3.7
LA-Nad NSCLC (n¼99)
L1 10424 46.9 29.3 0.6 10.5 0.2 1.5 11
L2 6790 40.6 27.6 5 5.8 0.6 9.3 11.1
R 554 0 0 0 0 90.9 0 9.1
PC 7140 0 0 0 0 0.5 95.2 4.3
Distant NSCLC (n¼140)
L1 10476 57 10 6.6 13.7 0.9 5.8 6
L2 6555 65.9 10.1 1.8 14.7 1.9 0 5.6
R 539 0 0 0 0 84.5 0 15.5
PC 5764 0 0 0 0 0.3 92.8 6.9
Local SCLC (n¼36)
L1 12436 42 27.9 1.6 14.9 2 0 11.6
L2 7311 62.5 13.6 0 11.1 5 0 7.7
R 684 0 0 0 25.4 59.5 0 15.1
PC 5279 0 0 0 0 0.6 85.7 13.7
Distant SCLC (n¼52)
L1 10718 52.1 8.8 3 26 4.1 0 6
L2 6100 72.2 7.6 0 5 7.4 1.3 6.5
R 596 0 0 0 0 89.4 0 10.6
PC 3521 0 0 0 0 0 90.4 9.6
NSCLC¼non-small-cell lung cancer; SCLC¼small-cell lung cancer; PC¼no active treatment; L1¼first-line treatment; L2¼second- or third-line treatment;
POM¼postoperative monitoring; R¼remission; PC¼no active treatment; Local Op¼Localised, initially operated; Local Nop¼localised, medically inoperable; LA-
Ad¼locally advanced, neoadjuvant treatment; A-Nad locally advanced nonsurgical; Distant¼disseminated; TC¼terminal care.
Table 3 Mean cost (US$), standard deviation and 95% confidence intervals (CI) of 18 months of management, and the cost of each management phase
Mean cost (SD; CI) L1 L2 R PC
Local Nop NSCLC 24443 (8650; 8327–48846) 8277 (33.8%) 5924 (24.2%) 503 (2.1%) 9739 (39.9%)
LA-Ad NSCLC 27794 (3146; 15918–25062) 15919 (57.3%) 8895 (32%) 442 (1.6%) 2538 (9.1%)
LA-Nad NSCLC 24579 (9327; 7140–52341) 14817 (60.3%) 4895 (19.9%) 607 (2.5%) 4260 (17.3%)
Diffuse NSCLC 20691 (9063; 5777–50380) 12913 (62.4%) 2714 (13.1%) 305 (1.5%) 4759 (23%)
Local SCLC 31833 (9984; 15866–64455) 21549 (67.7%) 4831 (15.1%) 1331 (4.2%) 4122 (12.9%)
Diffuse SCLC 20184 (7309; 3521–46393) 15058 (74.6%) 2091 (10.4%) 318 (1.6%) 2718 (13.4%)
Mean cost (SD; CI) POM L1 L2 R PC
Local Op NSCLC 25050 (9718; 10789–61930) 6840 (27.2%) 12625 (50.2%) 1803 (7.8%) 896 (3.6%) 2886 (11.2%)
NSCLC¼no small-cell lung cancer; SCLC¼small-cell lung cancer; PC¼no active treatment; L1¼first-line treatment; L2¼second- or third-line treatment;
POM¼postoperative monitoring; R¼remission; PC¼no active treatment, Local Op¼Localised, initially operated; Local Nop¼localised, medically inoperable; LA-
Ad¼locally advanced, neoadjuvant treatment; LA-Nad locally advanced nonsurgical; distant¼disseminated.
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lmedically inoperable localised and diffuse forms of NSCLC
(Table 4). The percentage of actively treated patients and the cost
of chemotherapy regimens used in first-line treatments impacted
more on MC than did the cost of chemotherapy used in second- or
third-line treatments, or the cost of palliative care.
DISCUSSION
This study shows that, during the first 18 months after diagnosis of
NSCLC and SCLC, patient management costs an average of US$
23262 and 27067, respectively. As previously reported (Wolsten-
holme and Whynes, 1999), the standard deviations and large CI
reflected the existence of two subgroups of patients, one of which
generated major costs (usually due to lengthy hospitalisation) and
the other only minor costs (owing to early death). Extrapolating
these sums to the entire French population, the cost of managing
lung cancer is thus US$0.53 billion yearly (0.4% of all health-care
spending). This model, based on a representative national sample
of patients with lung cancer, takes into account the main factors
influencing management costs, namely treatment modalities
(hospital-based or ambulatory care), refunding (private or public
sector) and health-care practices. This approach permits a robust
economic analysis reflecting the reality of patient management and
is a useful adjunct to previously published studies in this area, be
they purely descriptive (Goodwin and Shepherd, 1998) or model-
based (Evans et al, 1995).
Regarding NSCLC, some authors have attempted to estimate the
cost of patient management without the use of models (Hillner
et al, 1998; Wolstenholme and Whynes, 1999). Unfortunately, the
aims, methodology, data collection modalities and types of costs
examined differ markedly among these studies, making it difficult
to compare the results. The most ambitious and most compre-
hensive model-based study is that published by Evans et al (1995),
based on 1988 cost calculations. This work was regularly updated
to take into account practice changes (Evans et al, 1997; Evans,
1997, Earle and Evans, 1999), particularly by examining the impact
of neoadjuvant treatment for stage IIIA and chemoradiotherapy
for stage IIIB. Using the same model, and considering that 85% of
these patients received active treatment, the authors concluded
that these first-line treatments increased the mean 1-year cost of
patient management by 45.9–66.3% for stage IIIA disease and by
27.9% for stage IIIB disease. It should be stressed that this model
does not take into account the cost of treatment-related
complications or transport, which represented up to 26 and 15%,
respectively, of total costs per patient in our study. In our study,
first-line treatments represented, respectively, 57.3 and 60.3% of
the MC of managing these forms of NSCLC. For stage IV NSCL
(Earle and Evans, 1999), these authors estimated the MC of
patient management with the paclitaxel–cisplatin combination at
44756 Canadian dollars, that is, almost twice the cost that we
calculated in France (US$ 20184); but the Canadians postulated
that all patients received first-line treatment with this costly
combination.
Most importantly, our results are based on routine management
of a representative sample of newly diagnosed lung cancer patients
rather than on expert opinion, which does not necessarily reflect
actual practices. Thus, in our study, 48 and 25.9% of patients with
stage I and II NSCLC had a medical contraindication to surgery;
67% of those initially treated surgically and 99.2% of those with
locally advanced disease were actively treated with chemotherapy
and/or radiotherapy. In contrast, the corresponding proportions in
the Canadian model were 10, 15, 20 and 85%.
Regarding SCLC, interpretation of the available costing litera-
ture is hindered by problems of variable cost inclusions, health
systems and data expression (Graham and Boyages, 1993; Doyle
et al, 1996). Even if the management of SCLC is more consensual
than that of NSCLC, several studies confirm the broad range of
chemotherapy protocols prescribed (Sambrook and Girling, 2001).
Despite the lack of recommendations in this area, 35.2% of patients
with SCLC in our study received second-line treatment, while the
Canadian assumption (Evans et al, 1995) was that no second-line
treatment was given to such patients. In contrast, prophylactic
cerebral irradiation was used far less often in our population (33%
of localised forms and 0% of diffuse forms, compared to,
respectively, 70 and 30% in the Canadian model). An English
team recently published the most thorough work to date (Oliver
et al, 2001), consisting of a purely descriptive study limited to two
hospitals. It did not distinguish diffuse and localised forms, and
analysed 109 consecutive patients diagnosed with SCLC between
1994 and 1997 (91.7 and 17.4% of patients, respectively, received
first- and second-line treatment). The MC per patient was d11556
and, if one excludes the cost of diagnosis (d2022), phases L1, L2
and PC represented, respectively, 59.2, 9.2 and 23.9% of the total
cost values similar to those we obtained.
The advantage of the Markov approach is that it can model all
the items composing the cost of managing patients with lung
cancer, especially the percentage of actively treated patients, drug
costs and the number of chemotherapy cycles (Smith et al, 2001).
This is a major advantage, given the increasingly complex
management of lung cancer. The Markov model can also be used
to evaluate the economic impact of new antimitiotic drugs (which
are generally far more costly than reference treatments) and also
takes into account new modes of drug administration (in
particular, the use of oral treatments, which do not necessitate
hospitalisation and therefore reduce direct costs). Finally, new
palliative care structures, and especially home-based care (which is
far less costly than hospitalisation), would engender a moderate
cost reduction.
Our study has certain limitations. Being centred on the
economic consequences of patient management choices, the cost
of diagnosis (which is not influenced by treatment choices) was
not taken into account. In previous studies (Evans et al, 1995;
Oliver et al, 2001), these costs represented between 5 and 10% of
Table 4 Impact on the mean management cost of a lung cancer patient of a 730% variation in first-line (L1) chemotherapy costs and second- or
third-line (L2) chemotherapy costs and a 30% fall in palliative care (PC) costs
Mean cost (US$) L1 chemotherapy costs (%) L2 chemotherapy costs (%) PC costs (%)
Variation 730 730  30
Local Op NSCLC 25050 73.5 71.1  4
Local Nop NSCLC 24443 72.9 72.7  13.6
LA-Ad NSCLC 27794 76.5 73.1  2.9
LA-Nad NSCLC 24579 78.4 74.9  6.1
Diffuse NSCLC 20691 710.6 72.7  6.9
Local SCLC 31833 78.5 72.7  4.2
Diffuse SCLC 20184 711.7 72.3  4.2
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lthe total management costs. Moreover, our economic assessment
only covered the 18-month period following diagnosis. This is
longer than in most studies, which generally focused on initial
management costs or the first year after diagnosis, a period that
generates between 85 and 97% of total costs (Evans et al, 1995;
Oliver et al, 2001). The risk is that major costs are associated with a
few surviving patients who receive lengthy palliative care. The
Markov approach limits this weakness by allowing longer periods
to be modelled, using the MC of periods spent with palliative care.
Likewise, the Markov model can take into account late relapses of
surgically treated NSCLC by studying 20 cycles (corresponding to 5
years).
Our sample took into account the existence of both public and
private health insurance systems in France, and the type of health-
care centre. However, by limiting our sample to centres managing
more than 50 new cases annually, we induced a certain selection of
the population and practices, which probably led to an over-
estimation of the proportion of actively treated patients. None-
theless, the universal medical insurance system in France and the
management of most cancer patients by specialists tend to favour
more aggressive management. We excluded patients treated in
clinical trials, in which costs are unknown, although a recent study
showed little difference from routine clinical practice (Bennett et al,
2000).
Another limitation of our study was the outcome measure.
Indeed, we limited our analysis to financial costs, without seeking
to determine the utility of the different health states in which
patients find themselves during the course of their illness. Such
analyses are most useful for comparing therapeutic strategies
(Arikian et al, 1995), whereas our objective was to determine the
relative costs of the different phases of patient management.
CONCLUSION
The Markov model used in this study, based on actual lung cancer
management practices in France, yielded a precise cost analysis of the
different management phases of lung cancer patients, and an
assessment of the likely impact of future advances that are essential
for the effective management of chronic diseases such as lung cancer.
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